US FDA requests 33% budget increase to $4.3 billion

16 February 2011

As US President Barack Obama submitted his budget proposals on Monday, the Food and Drug Administration is requesting a budget of $4.3 billion to protect and promote the public health as part of the President's fiscal year 2012 budget - a 33% increase over the FDA enacted budget for FY 2010. The FY 2012 request covers the period of October 1, 2011, through September 30, 2012.

"FDA protects and promotes the health of all Americans through every stage of life," said FDA Commissioner Margaret Hamburg, adding: "The breadth of this mandate means that FDA responsibilities continue to grow. The new budget contains new resources so that FDA can fulfill its growing responsibilities to the American public."

The President’s proposals contain a number of provisions relating to generic patent settlements and the exclusivity of biologic drug copies, or biosimilars, which have angered the pharmaceutical industry (The Pharma Letter February 15).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Biotechnology